Neuroendocrine and cardiac metabolic dysfunction and NLRP3 inflammasome activation in adipose tissue and pancreas following chronic spinal cord injury in the mouse

ASN Neuro

Volumn 5, Issue 4, 2013, Pages 243-255

  Bigford, Gregory E ^a   Bracchi Ricard, Valerie C ^a   Keane, Robert W ^a   Nash, Mark S ^a   Bethea, John R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Metabolism; Neuroendocrine; Pathophysiology; Signal transduction; Spinal cord injury

Indexed keywords

CRYOPYRIN; INFLAMMASOME; JANUS KINASE 2; LEPTIN RECEPTOR; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; FEMALE; HEART DISEASE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTRAABDOMINAL FAT; METABOLIC DISORDER; MOUSE; NEUROENDOCRINE DISEASE; NONHUMAN; PANCREATITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; FEMALE; HYPOTHALAMUS; INFLAMMASOMES; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MYOCARDIUM; NEUROPEPTIDE Y; PANCREAS; PRO-OPIOMELANOCORTIN; RECEPTORS, LEPTIN; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; STAT3 TRANSCRIPTION FACTOR;

EID: 84886300618     PISSN: 17590914     EISSN: None     Source Type: Journal    
DOI: 10.1042/AN20130021     Document Type: Article

References (116)

1. Abel ED, Litwin SE, Sweeney G (2008) Cardiac remodeling in obesity. Physiol Rev 88:389-419.
2. Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW, Dietrich WD (2009) Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab 29:534-544.
3. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J (2004) NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319-325.
4. Ahima RS, Qi Y, Singhal NS (2006a) Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res 153:155-174.
5. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE (2006b) Brain adipocytokine action and metabolic regulation. Diabetes 55 (Suppl 2):S145-S154.
6. Atkinson LL, Fischer MA, Lopaschuk GD (2002) Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 277:29424-29430.
7. Barker BR, Taxman DJ, Ting JP (2011) Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol 23:591-597.
8. Bauman WA, Spungen AM (2001) Carbohydrate and lipid metabolism in chronic spinal cord injury. J Spinal Cord Med 24:266-277.
9. Bauman WA, Spungen AM, Zhong YG, Rothstein JL, Petry C, Gordon SK (1992) Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia 30:697-703.
10. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, Lai CF, Tartaglia LA (1996) The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A 93:8374-8378.
11. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL, Tomei LD, Hannun YA, Umansky SR (1997) Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 151:1257-1263.
12. Bigford GE, Bracchi-Ricard VC, Nash MS, Bethea JR (2012) Alterations in mouse hypothalamic adipokine gene expression and leptin signaling following chronic spinal cord injury and with advanced age. PLoS ONE 7:e41073.
13. Billington CJ, Briggs JE, Grace M, Levine AS (1991) Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 260:R321-R327.
14. Brenes G, Dearwater S, Shapera R, LaPorte RE, Collins E (1986) High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients. Arch Phys Med Rehabil 67:445-450.
15. Carlyle M, Jones OB, Kuo JJ, Hall JE (2002) Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 39:496-501.
16. Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn D, Rochford JJ, White A, Oliver RL, Millington G, Aparicio SA, Colledge WH, Russ AP, Carlton MB, O'Rahilly S (2004) Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A 101:4695-4700.
17. Chen Y, Henson S, Jackson AB, Richards JS (2006) Obesity intervention in persons with spinal cord injury. Spinal Cord 44:82-91.
18. Clark JE, Sarafraz N, Marber MS (2007) Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther 116:192-206.
19. Coll AP, Farooqi IS, Challis BG, Yeo GS, O'Rahilly S (2004) Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 89:2557-2562.
20. Cone RD (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578.
21. de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD, Keane RW (2008) A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci 28:3404-3414.
22. de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD, Keane RW (2009) Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab 29:1251-1261.
23. Deng Y, Scherer PE (2010) Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 1212:E1-E19.
24. DeVivo MJ, Krause JS, Lammertse DP (1999) Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 80:1411-1419.
25. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
26. Dinarello CA, Donath MY, Mandrup-Poulsen T (2010) Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 17:314-321.
27. Dubey L, Hesong Z (2006) Role of leptin in atherogenesis. Exp Clin Cardiol 11:269-275.
28. Edwards LA, Bugaresti JM, Buchholz AC (2008) Visceral adipose tissue and the ratio of visceral to subcutaneous adipose tissue are greater in adults with than in those without spinal cord injury, despite matching waist circumferences. Am J Clin Nutr 87:600-607.
29. Fei H, Okano HJ, Li C, Lee GH, Zhao C, Darnell R, Friedman JM (1997) Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci U S A 94:7001-7005.
30. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H (2008) Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 51:317-326.
31. Galas L, Tonon MC, Beaujean D, Fredriksson R, Larhammar D, Lihrmann I, Jegou S, Fournier A, Chartrel N, Vaudry H (2002) Neuropeptide Y inhibits spontaneous alpha-melanocyte-stimulating hormone (alpha-MSH) release via a Y(5) receptor and suppresses thyrotropin-releasing hormone-induced alpha-MSH secretion via a Y(1) receptor in frog melanotrope cells. Endocrinology 143:1686-1694.
32. Garg NJ (2011) Inflammasomes in cardiovascular diseases. Am J Cardiovasc Dis 1:244-254.
33. Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, Gagnon D, Brown R (2005) A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord 43:408-416.
34. Gezici AR, Ergun R, Karakas A, Gunduz B (2009) Serum leptin levels following acute experimental spinal cord injury. J Spinal Cord Med 32:416-421.
35. Goossens GH, Blaak EE, Theunissen R, Duijvestijn AM, Clement K, Tervaert JW, Thewissen MM (2012) Expression of NLRP3 inflammasome and T-cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 50:142-149.
36. Gorgey AS, Mather KJ, Gater DR (2011) Central adiposity associations to carbohydrate and lipid metabolism in individuals with complete motor spinal cord injury. Metabolism 60:843-851.
37. Groah SL, Nash MS, Ljungberg IH, Libin A, Hamm LF, Ward E, Burns PA, Enfield G (2009) Nutrient intake and body habitus after spinal cord injury: an analysis by sex and level of injury. J Spinal Cord Med 32:25-33.
38. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93:767-775.
39. Hof PR YW, Bloom FE, Belichenko, PB, Cello MR (2000) Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/Sv Mouse Brains. Amsterdam: Elsevier.
40. Hosoi T, Sasaki M, Miyahara T, Hashimoto C, Matsuo S, Yoshii M, Ozawa K (2008) Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 74:1610-1619.
41. Hou N, Luo JD (2011) Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol 38:905-913.
42. Huang TS, Wang YH, Chen SY (2000) The relation of serum leptin to body mass index and to serum cortisol in men with spinal cord injury. Arch Phys Med Rehabil 81:1582-1586.
43. Jeon JY, Steadward RD, Wheeler GD, Bell G, McCargar L, Harber V (2003) Intact sympathetic nervous system is required for leptin effects on resting metabolic rate in people with spinal cord injury. J Clin Endocrinol Metab 88:402-407.
44. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, Molkentin JD (2004) Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279:15524-15530.
45. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS (1991) Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci U S A 88:10931-10935.
46. Kerkela R, Force T (2006) p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol 48:556-558.
47. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M (2003) Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 23:656-660.
48. Korda M, Kubant R, Patton S, Malinski T (2008) Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 295:H1514-H1521.
49. Li G, Mobbs CV, Scarpace PJ (2003) Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 52:1951-1957.
50. Liang H, Chen D, Wang Y, Rimmer JH, Braunschweig CL (2007) Different risk factor patterns for metabolic syndrome in men with spinal cord injury compared with able-bodied men despite similar prevalence rates. Arch Phys Med Rehabil 88:1198-1204.
51. Lollmann B, Gruninger S, Stricker-Krongrad A, Chiesi M (1997) Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun 238:648-652.
52. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258.
53. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G (2006) Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 69:716-725.
54. Maggioni M, Bertoli S, Margonato V, Merati G, Veicsteinas A, Testolin G (2003) Body composition assessment in spinal cord injury subjects. Acta Diabetol 40 (Suppl 1):S183-S186.
55. Maimoun L, Puech AM, Manetta J, Badiou S, Paris F, Ohanna F, Rossi M, Sultan C (2004) Circulating leptin concentrations can be used as a surrogate marker of fat mass in acute spinal cord injury patients. Metabolism 53:989-994.
56. Maki KC, Briones ER, Langbein WE, Inman-Felton A, Nemchausky B, Welch M, Burton J (1995) Associations between serum lipids and indicators of adiposity in men with spinal cord injury. Paraplegia 33:102-109.
57. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A (2001) Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89:E41-E45.
58. Mantzoros CS (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130:671-680.
59. Marber MS, Molkentin JD, Force T (2010) Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov Today Dis Mech 7:e123-e127.
60. Mark AL, Correia ML, Rahmouni K, Haynes WG (2002) Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 20:1245-1250.
61. Maruyama Y, Mizuguchi M, Yaginuma T, Kusaka M, Yoshida H, Yokoyama K, Kasahara Y, Hosoya T (2008) Serum leptin, abdominal obesity and the metabolic syndrome in individuals with chronic spinal cord injury. Spinal Cord 46:494-499.
62. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621-668.
63. Mercer RE, Chee MJ, Colmers WF (2011) The role of NPY in hypothalamic mediated food intake. Front Neuroendocrinol 32:398-415.
64. Mizuno TM, Kelley KA, Pasinetti GM, Roberts JL, Mobbs CV (2003) Transgenic neuronal expression of proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes 52:2675-2683.
65. Mori-Kawabe M, Tsushima H, Fujimoto S, Tada T, Ito J (2009) Role of Rho/Rho-kinase and NO/cGMP signaling pathways in vascular function prior to atherosclerosis. J Atheroscler Thromb 16:722-732.
66. Moriki N, Ito M, Seko T, Kureishi Y, Okamoto R, Nakakuki T, Kongo M, Isaka N, Kaibuchi K, Nakano T (2004) RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 27:263-270.
67. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A (2001) Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 15:1062-1064.
68. Myers Jr MG, Olson DP (2012) Central nervous system control of metabolism. Nature 491:357-363.
69. Myers J, Lee M, Kiratli J (2007) Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil 86:142-152.
70. Nash MS, Mendez AJ (2007) A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. Arch Phys Med Rehabil 88:751-757.
71. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, van de Loo FA, Verschueren I, Pulawa L, Akira S, Eckel RH, Dinarello CA, van den Berg W, van der Meer JW (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 12:650-656.
72. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J (2000) Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36:501-505.
73. Nishi RA, Liu H, Chu Y, Hamamura M, Su MY, Nalcioglu O, Anderson AJ (2007) Behavioral, histological, and ex vivo magnetic resonance imaging assessment of graded contusion spinal cord injury in mice. J Neurotrauma 24:674-689.
74. Oswal A, Yeo G (2010) Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) 18:221-229.
75. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85-97.
76. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461.
77. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H (2008) Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294:H1804-H1814.
78. Prins JB (2002) Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab 16:639-651.
79. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML (2001) Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 185:195-204.
80. Rekhter M, Chandrasekhar K, Gifford-Moore D, Huang XD, Rutherford P, Hanson J, Kauffman R (2007) Immunohistochemical analysis of target proteins of Rho-kinase in a mouse model of accelerated atherosclerosis. Exp Clin Cardiol 12:169-174.
81. Ren J (2004) Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 181:1-10.
82. Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM (2004) Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 41:711-722.
83. Sainsbury A, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B (1997) Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats. Diabetes 46:209-214.
84. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N (2003) Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35:59-70.
85. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821-832.
86. Schroder K, Zhou R, Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-300.
87. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T (2003) Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 92:411-418.
88. Severson DL (2004) Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Physiol Pharmacol 82:813-823.
89. Sharma V, Mustafa S, Patel N, Wambolt R, Allard MF, McNeill JH (2009) Stimulation of cardiac fatty acid oxidation by leptin is mediated by a nitric oxide-p38 MAPK-dependent mechanism. Eur J Pharmacol 617:113-117.
90. Smart JL, Tolle V, Low MJ (2006) Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice. J Clin Invest 116:495-505.
91. Spungen AM, Adkins RH, Stewart CA, Wang J, Pierson Jr, RNWaters RL, Bauman WA (2003) Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. J Appl Physiol 95:2398-2407.
92. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7:1189-1192.
93. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, van den Berg S, Romijn J, Rensen PC, Joosten LA, Netea MG, Kanneganti TD (2011) Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 108:15324-15329.
94. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Muller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG (2010) The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12:593-605.
95. Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature 481:278-286.
96. Sweeney G (2010) Cardiovascular effects of leptin. Nat Rev Cardiol 7:22-29.
97. Troseid M, Seljeflot I, Arnesen H (2010) The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 9:11.
98. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179-188.
99. Wahman K, Nash MS, Lewis JE, Seiger A, Levi R (2011) Cardiovascular disease risk and the need for prevention after paraplegia determined by conventional multifactorial risk models: the Stockholm spinal cord injury study. J Rehabil Med 43:237-242.
100. Wang L, Tang X, Zhang H, Yuan J, Ding H, Wei Y (2011) Elevated leptin expression in rat model of traumatic spinal cord injury and femoral fracture. J Spinal Cord Med 34:501-509.
101. Wen H, Ting JP, O'Neill LA (2012) A role for the NLRP3 inflammasome in metabolic diseases -did Warburg miss inflammation? Nat Immunol 13:352-357.
102. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP (2011) Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12:408-415.
103. Wold LE, Relling DP, Duan J, Norby FL, Ren J (2002) Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 39:69-74.
104. Wu DJ, Xu JZ, Wu YJ, Jean-Charles L, Xiao B, Gao PJ, Zhu DL (2009) Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis 207:68-73.
105. Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF, Luo JD (2004) Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110:1269-1275.
106. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U (1999) Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5:1066-1070.
107. Youm YH, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit VD (2011) Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 152:4039-4045.
108. Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM (1997) Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A 94:1023-1028.
109. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B (1993) Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133:1753-1758.
110. Zeidan A, Javadov S, Karmazyn M (2006) Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 72:101-111.
111. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M (2008) Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc Res 77:64-72.
112. Zeidan A, Hunter JC, Javadov S, Karmazyn M (2011) mTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol Cell Biochem 352:99-108.
113. Zhang L, Bijker MS, Herzog H (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 131:91-113.
114. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D (2008) Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135:61-73.
115. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432.
116. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136-140.